Navigation Links
Farletuzumab Data Presented on Phase II Clinical Trial in First-Relapsed Ovarian Cancer Subjects
Date:9/24/2009

ort our commitment to continue to develop farletuzumab for ovarian cancer," said Nicholas C. Nicolaides, Ph.D., President and CEO of Morphotek. "Our research with farletuzumab is consistent with our human health care (hhc) mission - addressing unmet medical needs by developing new treatment options that will improve the lives of patients."

Study Details

The primary objectives of the open-label Phase II study included: to measure overall response rate (ORR), to compare the length of a subject's second remission with her first remission and to measure change in CA-125 level.( )Approximately 20 centers in the United States, Germany and the Netherlands participated in the study.

Thirty-nine (88.6%) of the 44 eligible subjects receiving farletuzumab in combination with platinum and taxane had their CA-125 blood levels normalized, and three additional subjects had a 50% decrease.( )(According to the National Cancer Institute, CA-125 is a tumor marker frequently elevated in ovarian cancer. It is typically used to evaluate tumor response, as CA-125 levels generally correlate with tumor activity.) In nine (20.5%) of these 44 subjects, the second remission was equal to or longer than the first remission.

About Ovarian Cancer

Ovarian cancer forms in the tissue of the ovary. Most ovarian cancers are epithelial carcinomas (cancer that begins in the cells on the surface of the ovary).

Ovarian cancer, which ranks fifth as the cause of cancer deaths in women, usually grows asymptomatically before it is discovered. In Europe, it is estimated that there are 61,000 cases of ovarian cancer each year. The National Cancer Institute estimates that there were 21,550 new cases of ovarian cancer in the United States in 2009 and 14,600 deaths from the disease.

About Farletuzumab

Farletuzumab (MORAb-003) is a humanized monoclonal antib
'/>"/>

SOURCE Morphotek(R), Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. OPAXIO(TM) Phase II Trial in Esophageal Cancer to be Presented in Proffered Session at the International Society of Gastrointestinal Oncology Annual Meeting
2. NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress
3. ClariVein(TM) Catheter for Varicose Veins: Further Clinical Trial Results to Be Presented
4. Bayer Announces New Data on Oncology Portfolio To Be Presented at the ECCO-ESMO Congress 2009
5. New Micro-Bland Embolization Technique with Embozene(TM) Microspheres to Be Presented at the International Medical Conference in Lisbon, Portugal
6. QVA149 Phase II Data Presented at the European Respiratory Society Annual Meeting
7. Data From Multiple Clinical Trials of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) to be Presented at TCT 2009
8. Data From Optimers Second Phase 3 Study of Prulifloxacin Presented at Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
9. Late Breaking Clinical Trials Presented at HFSA 13th Annual Scientific Meeting
10. Study on PLC Systems TMR Therapy With Stem Cells Presented at ESC 2009
11. Amgen Highlights Data to be Presented at American Society for Bone and Mineral Research (ASBMR) Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... 30, 2015   Regulus Therapeutics Inc . (NASDAQ: ... and development of innovative medicines targeting microRNAs, today announced ... the quarter ended March 31, 2015 on Thursday, May ... Regulus will host a conference call and ... Eastern Daylight Time to discuss its first quarter 2015 ...
(Date:4/30/2015)... CUPERTINO, Calif., April 30, 2015  DURECT Corporation (Nasdaq: ... first quarter of 2015.  Total revenues were $4.8 million ... months ended March 31, 2015 as compared to total ... million for the three months ended March 31, 2014.At ... $29.8 million, compared to cash and investments of $34.9 ...
(Date:4/30/2015)... 2015 Pharmacists at Osco Drug have voted to ... Portland, Maine . The newly organized group consists of ... Shaw,s supermarkets throughout Maine . ... in securing them the powerful representation that Teamsters Local 340 ... President of Local 340. "We will work tirelessly, providing them ...
Breaking Medicine Technology:Regulus Announces Timing for First Quarter 2015 Financial Results Webcast and Conference Call 2Regulus Announces Timing for First Quarter 2015 Financial Results Webcast and Conference Call 3DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 2DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 3DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 4DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 5DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 6DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 7DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 8DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 9
... 02, 2007 /PRNewswire-FirstCall/ - YM,BioSciences Inc. ... develops,and commercializes differentiated products for patients ... randomized,placebo-controlled Phase IIb trial of AeroLEF(TM) ... following orthopedic surgery.,AeroLEF(TM) met the primary ...
... 2, 2007 - Acorda Therapeutics, Inc.(R),(Nasdaq: ACOR) ... clinical trial,of Fampridine-SR in people with multiple ... meeting. Andrew Goodman, M.D.,Director of the Multiple ... top-line results on walking ability, leg,strength, spasticity ...
Cached Medicine Technology:YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets,Primary Endpoint in Patients with Post-Surgical Pain 2YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets,Primary Endpoint in Patients with Post-Surgical Pain 3Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 2Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 3Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 4Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 5Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 6Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 7
(Date:5/1/2015)... The Workgroup for Electronic Data Interchange ... use of health IT to create efficiencies in healthcare ... the United States Government Accountability Office (GAO) for a ... Medicare. The report, “ Potential Uses of Electronically Readable ... the public on Apr. 24, 2015 and examines the ...
(Date:5/1/2015)... Hope For The Warriors® thanks All ... The Warriors® and military families. All American Ford presented ... The Warriors®, a national nonprofit dedicated to restoring a ... hope for our service members and our military families. ... collected and matched small autograph fee from fans and ...
(Date:5/1/2015)... 2015 The Quail Creek Relay for Life ... Since 2001, the Quail Creek Relay team has raised almost ... throughout the year, including their biggest event, January’s Dinner and ... , Quail Creek Relay for Life team was established ... Kerwin, fitness director, states, “I was hooked when I learned ...
(Date:5/1/2015)... May 01, 2015 Digital technology and ... pregnant women between prenatal appointments, a preliminary study ... a small sample of low-risk pregnant women, will be ... Washington University Medical Faculty Associates at the 2015 American ... Scientific Meeting, May 2-6. The digital technology used was ...
(Date:5/1/2015)... Veteran Outreach Pittsburgh - Events , The ... VA Vet Centers on May 6, starting at 5 p.m., ... in front of the SouthSide Works Theater, 425 Cinema Drive, ... the documentary, “That Which I Love Destroys Me,” and a ... Please contact Robert Novotney for more information on the VA ...
Breaking Medicine News(10 mins):Health News:WEDI Contributes to Newly Released U.S. Government Accountability Office (GAO) Study on Potential Use of Electronically Readable Medicare Cards 2Health News:WEDI Contributes to Newly Released U.S. Government Accountability Office (GAO) Study on Potential Use of Electronically Readable Medicare Cards 3Health News:All American Ford Presents Donation to Nonprofit Hope For The Warriors 2Health News:Quail Creek Country Club’s Relay for Life Team Raised Over $89,000 for American Cancer Society 2Health News:Mobile Technology May Be Effective in Monitoring Pregnant Women Between Office Visits, Study Shows 2Health News:Mobile Technology May Be Effective in Monitoring Pregnant Women Between Office Visits, Study Shows 3
... Innovations, (Pink Sheets: SCLL) ACTIVTox(R) human liver toxicity tests ... standardized human liver cell line to identify potential toxicities ... is available now and can be used to help ... of our ACTIVTox testing system could help prevent recalls ...
... 21 Celator Pharmaceuticals today announced that it ... Inc. (Nasdaq: CEPH ). The ... application of Celator,s proprietary technology to an ongoing ... agreement provides an opportunity to leverage the technology ...
... MDdatacor, Inc ., a leader in health care ... today announced new functionality to support in tracking ... Care Program. The program is a collaboration between Wellmark ... to promote improved quality care and increased efficiency. ...
... Optimize Resources With Imaging, Behavioral and Chronic Management ... is now easier for providers and payors, thanks ... new Milliman Care Guidelines (R) 13th Edition. ... measures within the Care Guidelines, workflow ...
... are out the schoolroom door and off to the ... preventive steps to help protect their hearts.Prevention may be ... exercise, stay away from cigarettes and have check-ups.Be aware ... disorder known as Long QT Syndrome, research shows that ...
... Employer Interest in Their NicheDENVER, May 21 The ... their employees on international business trips to "get proactive" ... the state,s largest travel health provider."We are hearing from ... Reesman, president of Passport Health Colorado. "I think now ...
Cached Medicine News:Health News:FDA's Hydroxycut Recall Highlights the Need for Stem Cell Innovations' ACTIVTox Human Liver Testing 2Health News:FDA's Hydroxycut Recall Highlights the Need for Stem Cell Innovations' ACTIVTox Human Liver Testing 3Health News:Celator(R) Pharmaceuticals Initiates Research Agreement With Cephalon, Inc. 2Health News:Wellmark Leverages MDdatacor Technology to Streamline Immunization Tracking 2Health News:Wellmark Leverages MDdatacor Technology to Streamline Immunization Tracking 3Health News:Milliman Care Guidelines(R) Products Drive Efficiency Through Expanded Quality Tools 2Health News:Milliman Care Guidelines(R) Products Drive Efficiency Through Expanded Quality Tools 3Health News:Protect Your Kids' Hearts: Summer Activity Can Trigger Genetic Disorder, Say Results for Life, Sudden Cardiac Arrest Association 2Health News:Protect Your Kids' Hearts: Summer Activity Can Trigger Genetic Disorder, Say Results for Life, Sudden Cardiac Arrest Association 3Health News:H1N1 Scare Causes Businesses to Get Serious About Travel Health 2
... an easy-to-use, automated system that enables you ... for managing hemostatic disordersincluding D-Dimer, Von Willebrand ... reflex and rerun testing for greater efficiency ... our high-quality service to help your lab ...
... RX ACCUNET Embolic Protection System is designed ... filter control when performing carotid stenting interventions. ... based filter system that utilizes rapid exchange ... control the filter during catheter manipulations. It ...
Four disposable disc electrodes are pre-gelled and attached to wires in red, blue, black and green. 4mil carbon film, Ag/AgCl coated. Each package contains 20 individually sealed sets of four leads....
Lancet cut ultra sharp tip for low penetration resistance. Low noise and impedance level giving you a clear and reliable signal. Stainless steel needle, color coded attached lead wires. Needles sold ...
Medicine Products: